The Non Muscle Invasive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non Muscle Invasive Bladder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Muscle Invasive Bladder Market.

Some of the key takeaways from the Non Muscle Invasive Bladder Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non Muscle Invasive Bladder treatment therapies with a considerable amount of success over the years. 
• Non Muscle Invasive Bladder companies working in the treatment market are Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others, are developing therapies for the Non Muscle Invasive Bladder treatment 

• Emerging Non Muscle Invasive Bladder therapies in the different phases of clinical trials are- TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others are expected to have a significant impact on the Non Muscle Invasive Bladder market in the coming years.   
• In April 2022, A Phase I study of the Erdafitinib intravesicaldelivery system (TAR-2010) in patients with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer with SelectedFGFR Mutations or Fusions was started by Janssen Research & Development, LLC
• In the Phase Ib ADVANCED-1EXP expansion trial of TARA-002 for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS), Protara Therapeutics has started subject dosing.
• In October 2021, For the purpose of comparing the clinical safety and efficacy of APL-1202 as a single-agent oral treatment versus intravenous epirubicin hydrochloride infusion in patients with intermediate-risk non-muscle invasive bladder cancer, Asieris Pharmaceuticals started a multi-center, randomised, open-label, parallel-controlled Phase 3 clinical trial
• RTGel reverse-thermal hydrogel, our cutting-edge technology, is used in UGN-102 (mitomycin gel), an experimental formulation, to treat low-grade NMIBC. Phase III clinical trials are being conducted on UGN-102 to treat non-muscle invasive bladder cancer

Non Muscle Invasive Bladder Overview

Cancer is identified in the tissue that borders the inner surface of the bladder and is referred to as non-muscle invasive bladder cancer (NMIBC). The muscle in the bladder is not implicated. The sixth most prevalent cancer in the US is bladder cancer. In 2020, bladder cancer will be discovered in close to 81,000 Americans. Males are more likely than females to develop bladder cancer.

Get a Free Sample PDF Report to know more about Non Muscle Invasive Bladder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight

Emerging Non Muscle Invasive Bladder Drugs Under Different Phases of Clinical Development Include:

• TL-532: Tollys
• AU-011: Aura Biosciences
• UGN-102: UroGen Pharma
• Sasanlimab: Pfizer
• TARA-002: Protara Therapeutics
• VAX 014: Vaxiion Therapeutics
• Pemigatinib: Incyte Corporation
• Erdafitinib: Janssen Pharmaceuticals
• TLD 1433: Theralase Technologies
• PF-06801591: Pfizer
• Nivolumab: BristolMyers Squibb
• APL-1202: Asieris Pharmaceuticals

Route of Administration

Non Muscle Invasive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Non Muscle Invasive Bladder Pipeline Therapeutics Assessment

• Non Muscle Invasive Bladder Assessment by Product Type
• Non Muscle Invasive Bladder By Stage and Product Type
• Non Muscle Invasive Bladder Assessment by Route of Administration
• Non Muscle Invasive Bladder By Stage and Route of Administration
• Non Muscle Invasive Bladder Assessment by Molecule Type
• Non Muscle Invasive Bladder by Stage and Molecule Type

DelveInsight’s Non Muscle Invasive Bladder Report covers around 30+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non Muscle Invasive Bladder product details are provided in the report. Download the Non Muscle Invasive Bladder pipeline report to learn more about the emerging Non Muscle Invasive Bladder therapies

Some of the key companies in the Non Muscle Invasive Bladder Therapeutics Market include:

Key companies developing therapies for Non Muscle Invasive Bladder are – Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sasanlimab, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED therapeutics, and several others.

Non Muscle Invasive Bladder Pipeline Analysis:

The Non Muscle Invasive Bladder pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non Muscle Invasive Bladder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Muscle Invasive Bladder Treatment.
• Non Muscle Invasive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non Muscle Invasive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Muscle Invasive Bladder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non Muscle Invasive Bladder drugs and therapies

Non Muscle Invasive Bladder Pipeline Market Drivers

• Increase in the number of patients suffering from non-muscle invasive bladder cancer. Approximately 70-75%bladder cancers are non-muscle invasive bladder cancer (NMIBC), development of novel therapies and favorable government policies are some of the important factors that are fueling the Non Muscle Invasive Bladder Market.

Non Muscle Invasive Bladder Pipeline Market Barriers

• However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Non Muscle Invasive Bladder Market growth.

Scope of Non Muscle Invasive Bladder Pipeline Drug Insight    

• Coverage: Global
• Key Non Muscle Invasive Bladder Companies: Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others
• Key Non Muscle Invasive Bladder Therapies: TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others
• Non Muscle Invasive Bladder Therapeutic Assessment: Non Muscle Invasive Bladder current marketed and Non Muscle Invasive Bladder emerging therapies
• Non Muscle Invasive Bladder Market Dynamics: Non Muscle Invasive Bladder market drivers and Non Muscle Invasive Bladder market barriers 

Request for Sample PDF Report for Non Muscle Invasive Bladder Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services